Friday, July 4, 2025 7/4/2025

Intestinal Drug Transporters in Veterinary Animals

Award Number: R43FD007586
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Intestinal Drug Transporters in Veterinary Animals - Intestinal Drug Transporters in Veterinary Animals Intestinal transporters in the ATP Binding Cassette Family (ABC) reduce the absorption of many xenobiotics including prescription drugs. ABCG2 encodes BCRP, an important transporter that is highly expressed in the intestine as well as other barrier tissues such as the Blood Brain Barrier. BCRP limits the oral bioavailability of its substrates and therefore candidate drugs that are found to highly interact with BCRP are often discarded during drug development. Only those with limited or no interactions with BCRP are selected for further development. However, for veterinary drug development, cell lines expressing the appropriate species orthologs of BCRP are not available. Since species differences in the substrate and inhibitor selectivity of transporters are likely to occur, the lack of cell lines expressing species orthologs of transporters represents an enormous gap for veterinary drug development. The goals of this Phase I SBIR research are to create and characterize cell lines and yeast strains stably expressing veterinary animal BCRP from dog, cat, sheep and pig. The cell lines and yeast strains will serve as resources for drug developers, and will represent innovative “alternative methods, in support of replacement/reduction/refinement for activities involving animal research.” In studies under aim 1, we will create stable cell lines and yeast strains expressing the species orthologs of BCRP. In aim 2, we will create robust assays and use model substrates and inhibitors of BCRP to characterize species differences in the substrate and inhibitor specificity of the transporter. Methods used in the proposed studies include technologies for creation of cell lines stably expressing the transporter orthologs, and isotopic uptake and flux assays in cells. Yeast transformation procedures and cytotoxicity assays will also be applied. Collectively these studies will enable veterinary drug development by providing much needed cell lines for predicting drug absorption. The cell lines will reduce the reliance on trial-and-error experimental approaches in animals.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$68,698 )
2024	2022	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Food and Drug Administration Research	000	1	4/29/2024	NEW	-$68,698
														Subtotal = -$68,698

Issue Date FY: 2022 ( Subtotal = $168,400 )
2022	2022	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Food and Drug Administration Research	000	1	9/26/2022	NEW	$168,400
														Subtotal = $168,400

Grand Total All Awards = $99,702

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Intestinal Drug Transporters in Veterinary Animals

Award Number: R43FD007586

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer